Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffyImmune Enrolls First Patient in Phase I Clinical Trial of AIC100 CAR T cells for the Treatment of Advanced, Refractory Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"Weill Cornell Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"ORI Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by AffyImmune Therapeutics

    Menu

    AffyImmune Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              AffyImmune Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital

              Details:

              The funding will be used to advance the Phase 1 study of AffyImmune’s lead asset, AIC100, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.

              Lead Product(s): AIC100

              Therapeutic Area: Oncology Product Name: AIC100

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: ORI Capital

              Deal Size: $30.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing October 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AffyImmune Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer

              Details:

              The FDA's Fast Track designation is designed for AIC100 facilitate development and expedite review of drug candidates to treat serious conditions and address an unmet medical need.

              Lead Product(s): AIC100

              Therapeutic Area: Oncology Product Name: AIC100

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Weill Cornell Medicine

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AffyImmune Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AffyImmune Enrolls First Patient in Phase I Clinical Trial of AIC100 CAR T cells for the Treatment of Advanced, Refractory Thyroid Cancer

              Details:

              The study is being conducted at Weill Cornell Medicine. Unlike most CAR-T cell products, AIC100 was designed to specifically target tumor cells overexpressing the target (ICAM-1) while avoiding normal cells expressing lower levels.

              Lead Product(s): AIC100

              Therapeutic Area: Oncology Product Name: AIC100

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY